# C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-the-8th-annual-evercore-healthcare-conference-409f1b8d
Ticker: CCCC
Company: C4 Therapeutics
Source: C4 Therapeutics
Published: 2025-11-25 12:00 EST
## Summary

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...

## Article Body
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida.

Fireside Chat Details: Event: 8 th Annual Evercore Healthcare Conference Date/Time: Wednesday, December 3 rd , 2025 at 3:25 pm ET

A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com . An archived replay of the webcast will be available for approximately 90 days following the live event.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:

Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com

Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com
## Recent Company News
- 2026-06-11 11:00 EST — [C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population](https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-202-2551b658) — Source: C4 Therapeutics
- 2026-05-20 11:00 EST — [C4 Therapeutics to Participate in Upcoming Conferences](https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-conferences-10ae0b56) — Source: C4 Therapeutics
- 2026-05-18 20:01 EST — [C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70d8c55a) — Source: C4 Therapeutics
- 2026-05-12 11:00 EST — [C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-dc6ffcc8) — Source: C4 Therapeutics
- 2026-04-09 10:59 EST — [C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaborati-b523cd96) — Source: C4 Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)